U.S. Hyaluronic Acid Based Dermal Fillers Market Size, Share & COVID-19 Impact Analysis, By Crosslinking Type (Monophasic and Biphasic), By Application (Scar Treatment, Wrinkle Correction Treatment, Lip Enhancement, Restoration of Volume/Fullness, and Others), By End-user (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others), and Country Forecast, 2023-2030

The U.S. hyaluronic acid based dermal fillers market size was worth USD 1.53 billion in 2022 and is projected to grow at a CAGR of 8.2% during the forecast period.

Hyaluronic acid based dermal fillers are injectable dermal fillers used to restore volume and smooth wrinkles in the skin, leveraging the hydrating and plumping properties of hyaluronic acid.

The rising awareness among the general population, particularly women and growing per capita income in the nation is poised to surge the demand for minimally invasive cosmetic procedures. The increasing number of cosmetic procedures is expected to boost the demand for these fillers in the market. 

Furthermore, the companies operating in the U.S. hyaluronic acid based dermal fillers market are continuously developing novel products and bringing advancements in hyaluronic acid based dermal fillers to offer new, effective products to provide patients with increasingly better results. This factor is primarily responsible for the demand for these dermal fillers in the market.

In 2020, the market faced a decline in the country during the COVID-19 pandemic. The decline is due to the low admission rate for anti-aging treatment and cancellations in non-invasive elective surgeries during the pandemic.

U.S. Hyaluronic Acid Based Dermal Fillers Market Trends

Increasing Demand for Hyaluronic Acid Dermal Fillers among Young People 

The surging awareness of aesthetic procedures, especially among young people, is one of the factors impacting the uptake of fillers, which may help them achieve a beauty standard goal across the country. People between the ages of 20 and 29 often opt for these procedures to prevent aging by smoothing the skin or treating wrinkles.

Moreover, this factor has boosted the emphasis of market players toward the research and development of novel dermal fillers consisting of hyaluronic acid for the young age population.

• For instance, in February 2022, Allergan Aesthetics (AbbVie, Inc.) unveiled the approval for JUVÉDERM VOLBELLA XC by the U.S. FDA. The product is indicated for adults above the age of 21 to treat infraorbital hollows.

U.S. Hyaluronic Acid Based Dermal Fillers Market Growth Factors 

Surge in the Number of Minimally Invasive Procedures to Propel Market Growth

In the U.S., the general population are increasingly seeking non-surgical options to address facial aging concerns, contributing to the rising popularity of minimally invasive procedures. Hyaluronic acid based dermal fillers, known for their effectiveness in restoring volume, smoothing wrinkles, and enhancing facial contours, have emerged as one of the primary options among the population.

The growing aging population in the country is expected to boost the demand for facial rejuvenation treatments. Moreover, the surge in research studies of these fillers and their positive outcomes, along with the ongoing approvals by the FDA for the products, is expected to propel market growth.

• For instance, according to the American Society for Dermatologic Surgery study, in December 2021, the hyaluronic acid filler VYC-20l was found to be effective and safe for cheek augmentation.

The confluence of these factors is slated to impel the U.S. hyaluronic acid based dermal fillers market growth in the coming years.

RESTRAINING FACTORS

Availability of Alternative Dermal Fillers May Restrain Market Growth 

The growth of the U.S. hyaluronic acid based dermal fillers market faces challenges due to the presence and increasing popularity of alternative dermal fillers. These alternative fillers, such as collagen-based dermal fillers and calcium hydroxylapatite (CaHA), are gaining their adoption in attracting a segment of the population seeking a more durable option compared to the temporary nature of HA-based fillers.

Furthermore, dermal fillers containing hyaluronic acid-based formulations are limited to the treatment of certain skin wrinkles, such as frown lines, dynamic wrinkles, crow’s feet, and glabellar lines, and have a short lifespan. There may also be concerns regarding the side effects of these procedures. However, another alternative filler, Botulinum toxin type A dermal fillers, leads to non-surgical cosmetic procedures in the U.S. due to their effectiveness, patient satisfaction, and use of skin grafts.

In the U.S., the number of hyaluronic acid based dermal fillers procedures performed in 2022 was 521,169, which was 1,671,605 procedures in 2021.

U.S. Hyaluronic Acid Based Dermal Fillers Market Segmentation Analysis

By Crosslinking Type Analysis

By crosslinking type, the market is segregated into biphasic and monophasic.

The monophasic segment occupied the largest U.S. hyaluronic acid based dermal fillers market share in 2022. The segment expansion can be credited to the growing number of minimally invasive surgical procedures along with the surge in the introduction of new monophasic HA-based products across the nation.

The biphasic segment held a significant share of the market in 2022. The growth is owing to the surge in FDA approvals for biphasic HA-based dermal fillers in the country.

• For instance, in June 2021, Galderma received the U.S. Food and Drug Administration (FDA) approval for Restylane Contour to correct midface contour deficiencies and cheek augmentation.

By Application Analysis

In terms of application, the market is classified into lip enhancement, wrinkle correction treatment, scar treatment, restoration of volume/fullness, and others.

The wrinkle correction treatment segment witnessed the largest share in 2022 and is expected to grow at the highest CAGR during the forecast timeframe. The expansion is  credited to the increasing spending on cosmetic surgeries in the country, along with the growing geriatric population seeking wrinkle treatments.

The lip enhancement segment held a substantial U.S. hyaluronic acid based dermal fillers market market share in 2022. The growth of this segment is due to the increasing launches of fillers containing hyaluronic acid for specific lip enhancement and the rising demand for aesthetic treatment for lips.

By End-user Analysis

By end-user, the market is classified into specialty & dermatology clinics, hospitals & clinics, and others.

The specialty & dermatology clinics accounted for the largest market share in 2022 and is poised to witness the highest CAGR during the forecast period. The expansion is due to the growing number of hyaluronic acid based filler procedures and the increasing incidence of aesthetic concerns such as wrinkles, scars, and acne.

The hospitals & clinics segment is anticipated to grow at a substantial CAGR during the forecast period. The segmental growth is attributed to the growing number of injectable cosmetic procedures in hospitals and the rising number of hyaluronic acid based dermal fillers in the market.

• For instance, as per the report published by the International Society of Aesthetic Plastic Surgery, the number of injectable procedures performed in the U.S. was 4,556,970 in 2022, which was 4,284,472 in 2021.

List of Key Companies in U.S. Hyaluronic Acid Based Dermal Fillers Market

With respect to the competitive landscape, the U.S. market for hyaluronic acid based dermal fillers showcases the presence of emerging and key players. Galderma, Merz Pharma, and Allergan (AbbVie) are the prominent players in the market. Allergan (AbbVie) is one of the leading players on account of its wide portfolio of hyaluronic acid based dermal fillers and robust direct presence.

Some other players with a considerable presence in the U.S. hyaluronic acid based dermal fillers market include Sinclair Pharma, Teoxane, and other medium & small-sized companies. These players are emphasizing strategic moves, including strengthening their distribution channel, which is anticipated to propel their market share.

LIST OF KEY COMPANIES PROFILED:

• Allergan Aesthetics (AbbVie Inc.) (U.S.)


• Revance Therapeutics, Inc. (U.S.)


• Merz Pharma (Germany)


• Galderma (Switzerland)


• Sinclair Pharma (U.K.)


• Prollenium Medical Technologies (Canada)


• Teoxane (Switzerland)

KEY INDUSTRY DEVELOPMENTS:

• January 2023: Allergan Aesthetics (AbbVie Inc.) launched JUVÉDERM VOLUX XC to treat loss of jawline definition in adults above the age of 21.


• January 2022: Teoxane received the U.S. FDA approval for RHA Redensity. The product is for the treatment of dynamic perioral rhytids in adults aged 22 or older. 


• January 2020: Teoxane announced a U.S. distribution agreement with Revance Therapeutics, Inc. to distribute its HA-based dermal fillers in the country.

REPORT COVERAGE

The report provides a detailed analysis of the market. It focuses on key aspects, an overview of regulatory and reimbursement scenarios, the number of HA-based dermal filler procedures, and market dynamics. In addition, it includes an overview of market segments, new product launches, and key industry developments such as mergers and acquisitions in the market. Besides this, the report also offers insights into the impact of the COVID-19 pandemic on the market’s growth.

Report Scope & Segmentation